Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 12;116(2):299–308. doi: 10.1093/jnci/djad186

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)

PMC Copyright notice

Figure 3. — Clinical outcomes of metastatic early-onset (age <50 years) and average-onset (age ≥50 years) esophagogastric cancer, restricted to adenocarcinoma and signet ring cell/diffuse–type tumors. A) Overall survival from the time of metastasis to the time of death or last follow-up did not differ statistically significantly between patients with early-onset compared with average-onset disease (median overall survival = 22.7 vs 22.1 months; P = .78 by log-rank test). B) Overall survival stratified by disease site showed that overall survival from time of metastasis to time of death or last follow-up was statistically significantly longer in patients with early-onset esophageal/gastroesophageal junction cancers and statistically significantly shorter in patients with early-onset gastric cancer (median overall survival = 32.0 vs 19.8 months, P = .02). C) Peritoneal metastasis was statistically significantly more common in the early-onset group than in the average-onset group (40.3% vs 23.8%, P < .001) and within the early-onset group occurred much more frequently in the gastric cancer group than in the esophageal/gastroesophageal junction cancer group (56.3% vs 15.9%, P < .001). D) Multivariate model generated based on variables that were statistically significant on univariate analysis demonstrated that more than 1 metastasis site and CDKN2A alterations were associated with worse outcomes. AO = average onset; CI = 95% confidence interval; CIN = chromosomal instability; EBV = Epstein-Barr virus; EO = early onset; GEJ = gastroesophageal junction; GS = gastric cancer; met = metastasis; MSI = microsatellite instability.